By Marie Rosenthal, MS
In a 21-0 vote with one abstention, the FDA Vaccines and Related Biological Products Advisory Committee (VRBPAC) recommended the agency grant an emergency use authorization (EUA) to NVX-CoV2373, the Novavax adjuvanted COVID-19 vaccine. It would be administered in a two-dose series.
If the FDA grants the EUA, the NVX-CoV2373 would become the first protein-based recombinant COVID-19 vaccine available in the United States.
The committee reviewed data from the pivotal phase 3